Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies - Wikidata - wikimedia - TriplyDB

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies

http://www.wikidata.org/entity/Q36750045

about

Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10 Harnessing the protective potential of HIV-1 neutralizing antibodies Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection Recent strategies targeting HIV glycans in vaccine design Advances in structure-based vaccine design Structural insights on the role of antibodies in HIV-1 vaccine and therapy Antibodies in HIV-1 vaccine development and therapy Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection Virological features associated with the development of broadly neutralizing antibodies to HIV-1 HIV broadly neutralizing antibody targets Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1 HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.Current views on the potential for development of a HIV vaccine.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.The Antibody Germline/Maturation Hypothesis, Elicitation of Broadly Neutralizing Antibodies Against HIV-1 and Cord Blood IgM Repertoires Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.The immune space: a concept and template for rationalizing vaccine development.Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.

P2860

Q21089590-2C0A6ACF-8D13-4348-A376-A84541F12457 Q26766153-7179614A-857A-4768-834B-22E6DAFD38FD Q26775082-FE82C02A-3664-4048-ABF0-A3B9519AD285 Q26823603-6B830C57-88C4-4A57-AE60-A8809246316D Q26824545-F6B043F9-7368-4D79-A23B-4B63220DF0FB Q26829461-4123B8D3-3210-4FFD-83AB-25B0A1E42DBB Q27011574-C65A37DA-5852-4000-A493-8BAAF2E3ADC3 Q27022652-25EA7D5C-BCBD-4E5B-964D-8EA398ADCE65 Q27025177-F4744923-4156-4246-844B-78C8E6EB5985 Q27026662-39B234E2-A809-47F4-B148-44C048FFFFB4 Q27319450-1B4D5446-0EA8-402C-B023-3B71B749DED1 Q27322403-EA92EF1A-36F9-4CB3-9453-8992F00B521B Q27324184-473740DF-4EF8-46CE-BA08-9DA4521DCDC6 Q27643993-8E772384-C69F-494A-A092-295586CCCE84 Q27644415-60FC765F-7E37-42D5-93D1-6C7A959E5382 Q27644634-0BD2DBB2-D685-4A96-A06B-38E70CEAC068 Q27679353-DA9A1CB4-0D92-4E33-990D-C05F8EB759F0 Q27680497-0B2C768C-042C-43EF-AE7F-A52012E960EB Q27680499-5CA02D34-ACF8-426C-8B8B-DC186ECB5CB6 Q27728037-9373DB1E-97A5-4734-B0D2-FD4B34D54C9C Q30223578-C5EF5DB4-4D55-4548-BE02-8881725392AB Q30234773-8DEBCD4B-6CC2-4AF9-8CE1-E84768BB8E1E Q30353580-674C05C1-8996-4632-861F-8C0109E44BBD Q30355260-98F00A1A-E16B-4693-9F9D-74E29D1EE064 Q30362489-A25EA6E7-9C23-4812-B9F6-1982D208E55F Q30393763-4A93EB83-C483-44CF-A473-19DA6196E190 Q30397595-30BD58FE-BD19-4AAB-AC92-81C22522779C Q30490942-B58F4E2F-2C7E-4C14-B64C-7093BA60A6A2 Q33683203-2BAE3459-55AE-4AA3-B477-D5086AF449C0 Q33753573-176F1670-3800-4E44-9D6B-D3E008D93E35 Q33821896-723C0A0B-EEED-4E1E-8579-B4A6D50935D4 Q33907694-D61823CF-BB27-4A16-8703-3DD260D58390 Q34022578-35B0A87B-297E-40D9-96C1-D972E473E3E7 Q34101087-7C22EABF-D6A4-445C-AC16-28F5CE706208 Q34133551-641FC390-A861-429A-B1C5-F8A2D11431DC Q34399762-FA3E5301-46DA-43BA-AA2A-36761D701005 Q34533041-6C697CE6-E0F2-4758-BD1D-380F7D7B2339 Q34555891-5B777C06-A80A-422E-9B23-BE860374D2AC Q34593647-A7F1685E-9ED5-43F0-ADA5-A1015B50CE77 Q34594513-A09290B4-C2CD-4D73-AF33-01B5FA939370

P2860

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies

http://www.wikidata.org/entity/Q36750045

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Engineering HIV envelope prote ...... ti-CD4 binding site antibodies

@en

type

label

Engineering HIV envelope prote ...... ti-CD4 binding site antibodies

@en

prefLabel

Engineering HIV envelope prote ...... ti-CD4 binding site antibodies

@en

P1433

Q36750045-E1B4E2B7-6EFE-40DC-8848-40EBB60BDF25

P1476

Q36750045-F379A77E-C348-4B67-A5FC-455ECD03D2BD

P2093

Q36750045-00B6BAD0-E012-4545-8F48-613DEE47858E

Q36750045-0DDBA307-C9F2-4966-8455-043CF11B3B87

Q36750045-10DDB54E-E057-4D35-AA75-2842BFC2E836

Q36750045-3E7E2ABC-F0C6-49F7-A548-F4471EA26B6E

Q36750045-3FF5E13E-7ABF-422E-818C-4C2BCC297200

Q36750045-6912B9DF-E4DD-46C4-8BF2-04254473396D

Q36750045-69717566-20F8-44BC-B7BA-EC80603B41DB

Q36750045-81AF1E5A-4EAB-4C44-A924-988BA6283D67

Q36750045-9DE8B2F3-72E4-4661-9BB8-EF847865ED8E

Q36750045-AAD45AAC-2FE4-4803-A57B-C7835FAC556A

P2860

Q36750045-0A798B9C-6BD8-43D3-829C-B16164D88C7E

Q36750045-0C0232D8-CFEA-457F-AB8D-DEFCF1353BD2

Q36750045-14F398AC-9AAF-46D1-A584-90A9683CCE6E

Q36750045-192EB3AB-CA10-457E-A5A1-4298DE7E4F72

Q36750045-1B7C9E4F-44B7-45C8-B902-65D74BFB5ADE

Q36750045-1F324A97-1B86-4B91-A806-6951083241F7

Q36750045-26CBF16F-FF1C-4797-B976-B2390DBB94FC

Q36750045-27483994-DCA7-4F77-8F48-3D73A0DD753C

Q36750045-2FE4E479-421F-4BB2-BD5B-66A69DC2B123

Q36750045-40DEBDD2-FD9A-465D-9D49-51EE004E18F4

P304

Q36750045-13E29DE7-9B83-437F-99A9-B6330CBFE70E

P31

Q36750045-75F291F5-D28F-4E77-9343-3691F9C39E9F

P356

Q36750045-1DE61B5A-E573-4DFA-856B-AA849C3CBDF4

P407

Q36750045-CCB1D091-174D-4105-95DE-5F8519A1E78F

P433

Q36750045-70982A12-536E-4999-8EEB-A16E1C1A30CE

P478

Q36750045-C0639D23-6673-4C14-8F10-FB53AAB9F577

P50

Q36750045-CEE78B73-E8DF-4EC7-9CC2-E8722F741D46

P577

Q36750045-DEFD385E-D14E-4DDF-9444-1C9BD5717271

P5875

Q36750045-69916AC8-6961-40CB-833E-76977056AFD9

P698

Q36750045-11FBCB0B-E5BC-42F0-BB91-2197933A24F2

P921

Q36750045-749CFB59-F274-4118-A126-2B9B19F21A80

P932

Q36750045-3FEAD1C4-38D0-4045-8EEA-2EFD0F62BF50

P356

P1433

Journal of Experimental Medicine

P1476

Engineering HIV envelope prote ...... ti-CD4 binding site antibodies

@en

P2093

Adriana Lippy

http://www.w3.org/2001/XMLSchema#string

Andrew Stuart

http://www.w3.org/2001/XMLSchema#string

Anita M Dreyer

http://www.w3.org/2001/XMLSchema#string

Anthony P West

http://www.w3.org/2001/XMLSchema#string

Johannes F Scheid

http://www.w3.org/2001/XMLSchema#string

Joseph Jardine

http://www.w3.org/2001/XMLSchema#string

Kristen W Cohen

http://www.w3.org/2001/XMLSchema#string

Leonidas Stamatatos

http://www.w3.org/2001/XMLSchema#string

Sam Hoot

http://www.w3.org/2001/XMLSchema#string

Sergey Menis

http://www.w3.org/2001/XMLSchema#string

P2860

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Characteristics of the earliest cross-neutralizing antibody response to HIV-1.

The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

RosettaRemodel: a generalized framework for flexible backbone protein design.

Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs

P304

655-663

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20122824

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

210

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236081812

http://www.w3.org/2001/XMLSchema#string

P698

23530120

http://www.w3.org/2001/XMLSchema#string

P921

P932

3620356

http://www.w3.org/2001/XMLSchema#string